Clinical Outcomes and Stroke Recurrence in Moyamoya Disease Post-Revascularization: A Retrospective Analysis

This study aimed to assess the clinical characteristics, treatment outcomes, and recurrence risks in moyamoya disease (MMD) patients, focusing on the impact of revascularization and antiplatelet therapy.

Forty-six MMD patients were analyzed. Data on demographics, clinical characteristics, treatment outcomes, and recurrence rates of ischemic and hemorrhagic strokes were collected. The effectiveness of revascularization and the role of antiplatelet therapy in preventing recurrent strokes were statistically evaluated.

The mean age was 19.5 years. Right-side weakness (28.3%) and left-side weakness (21.7%) were common symptoms. Pre-revascularization, recurrent ischemic strokes affected 58.7% of patients; post-revascularization, the incidence dropped to 8.7%. However, a high recurrence rate (39.1%) persisted among those not undergoing surgery. Post-revascularization hemorrhagic strokes were rare (6.5%). Antiplatelet therapy significantly reduced ischemic stroke recurrence (P < 0.001) and hemorrhagic stroke risk.

Early intervention and continuous antiplatelet therapy are crucial in managing MMD. Despite reduced ischemic stroke recurrence post-revascularization, functional outcomes often remained unimproved, indicating the need for optimized treatment strategies.